Literature DB >> 24211164

Dasatinib and docetaxel in advanced prostate cancer.

Primo N Lara1, Christopher P Evans.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24211164     DOI： 10.1016/S1470-2045(13)70500-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Authors:  P N Lara; M Plets; C Tangen; E Gertz; N J Vogelzang; M Hussain; P W Twardowski; M G Garzotto; J P Monk; M Carducci; A Goldkorn; P C Mack; I Thompson; M Van Loan; D I Quinn
Journal:  Cancer Treat Res Commun       Date:  2018-04-28

Review 2.  SRC: marker or actor in prostate cancer aggressiveness.

Authors:  Virginie Vlaeminck-Guillem; Germain Gillet; Ruth Rimokh
Journal:  Front Oncol       Date:  2014-08-18       Impact factor: 6.244

3.  Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.

Authors:  Chih-Cheng Yang; Ladan Fazli; Salvatore Loguercio; Irina Zharkikh; Pedro Aza-Blanc; Martin E Gleave; Dieter A Wolf
Journal:  Oncotarget       Date:  2015-09-08

Review 4.  Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases.

Authors:  Irwin H Gelman
Journal:  Int J Biol Sci       Date:  2014-06-05       Impact factor: 6.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.